Gyros Expands Asian Distribution to Singapore

06-Jun-2012

Gyros’ nanoliter-scale immunoassay platform now available to biopharmaceutical companies in Singapore region.

Gyrolab™ xP workstation (www.gyros.com) is used by major biopharmaceutical companies and their service providers worldwide to improve productivity and efficiency during the development of biotherapeutics and vaccines, boosting time-critical workflows and helping to meet regulatory demands.

“We are very pleased to expand our reach in Asia through this new partnership with Bio Laboratories, which provides a valuable addition to our recently announced collaboration with GE Healthcare for distribution in Japan, China, Taiwan and Hong Kong,” commented Erik Walldén, CEO, Gyros. “As our immunoassay platform increases in acceptance within the biopharmaceutical industry, it is ever more vital that we have an experienced and respected network of distributors to ensure the highest possible standards of service and support for our customers.”

Benny Wee, Managing Director, Bio Laboratories, said, “Gyros’ immunoassay platform is an excellent addition to our extensive range of distribution agreements with high quality, innovative analytical instrument providers. We are delighted to be able to now offer Gyros’ products to the biopharmaceutical industry in Singapore.”

For Bio Laboratories Pte Ltd

Benny Wee

Managing Director

Tel: +65 6846 7577

Email: benny_wee@biolab.com.sg

www.biolab.com.sg

About Bio Laboratories Pte Ltd (www.biolab.com.sg)

Bio Laboratories is a leading distributor of medical, scientific and life science products in Singapore. We focus on serving customers through the innovative and responsible application of science and technology. Bio Laboratories prides itself on its efficient service and technical service support.

With its suppliers as business partners, one of Bio Laboratories goals is to bring new technologies into the market which will benefit its customers and in the process grow its overall business. This is the reason for our existence. We believe in long-term partnership with our customers and business partners based on mutual trust and respect.

 

 


Enquiries:
For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: katie.odgaard@zymecommunications.com / lorna.cuddon@zymecommunications.com
www.zymecommunications.com


Notes to editors:
About Gyros (www.gyros.com)

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.